ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine-1-phosphate receptor modulators and proteasome inhibitors).

Document types check

Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12530/37834

Title:	ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine-1-phosphate receptor modulators and proteasome inhibitors).
Authors:	Redelman-Sidi, G Michielin, O Cervera, C Ribi, C Aguado, J M Fernández-Ruiz, M Manuel, O View more
Keywords:	Alefacept Fingolimod Infection Ipilimumab Natalizumab Nivolumab Pembrolizumab Progressive multifocal leukoencephalopathy Proteasome inhibitors Vedolizumab View more
Mesh:	Antibodies, Monoclonal Antibodies, Monoclonal, Humanized Biological Therapy CTLA-4 Antigen Cell Adhesion Clinical Trials as Topic Communicable Diseases Consensus Genes, cdc Humans Immunocompromised Host Leukoencephalopathy, Progressive Multifocal Molecular Targeted Therapy Natalizumab Proteasome Inhibitors Receptors, Lysosphingolipid View more
Issue Date:	Jun-2018
Citation:	Clin. Microbiol. Infect..2018 Jun;(24 Suppl 2):S95-S107
Abstract:	The present review is part of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Infections in Compromised Hosts (ESGICH) consensus document on the safety of targeted and biological therapies.
PMID:	29427804
URI:	https://hdl.handle.net/20.500.12530/37834
Rights:	openAccess
Appears in Collections:	Hospitales > H. U. 12 de Octubre > Artículos Fundaciones e Institutos de Investigación > IIS H. U. 12 de Octubre > Artículos

Files in This Item:

File	Description	Size	Format
PMC5971148.pdf		490.11 kB	Adobe PDF	View/Open